PDCD1 and melanoma: According to the literature, a phase II study [40] showed that adoptive transfer of autologous TILs in patients with unresectable melanoma refractory to anti-PD-1 therapy induced objective clinical responses in 36% of patients (2 CR) and that the majority of the responses were durable, with a median duration of response not reached.